Current Report · Items 7.01, 8.01, 9.01 · 8-K
Precision BioSciences, Inc.
DTILNASDAQEQUITYCurrent
Regulation FD Disclosure · Other Events
Item 7.01 Regulation FD Disclosure On August 24, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (“DMD”) at Arkansas Children’s Hospital. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Filed Aug 24, 2026Accepted Aug 24, 2026, 7:00 AM EDTCIK 1357874Accession 0001628280-26-058512
Company context
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of
Current securities
Disclosure sections
Items 7.01, 8.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On August 24, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (“DMD”) at Arkansas Children’s Hospital. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, this Item 7.01 (including the Press Release attached hereto as Exhibit 99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any registration statement or other filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events
On August 24, 2026, the Company issued a press release announcing the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of DMD.